JP2013538566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538566A5
JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
dom7h
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063999 external-priority patent/WO2012020143A1/en
Publication of JP2013538566A publication Critical patent/JP2013538566A/ja
Publication of JP2013538566A5 publication Critical patent/JP2013538566A5/ja
Pending legal-status Critical Current

Links

JP2013523643A 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体 Pending JP2013538566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37339710P 2010-08-13 2010-08-13
US61/373,397 2010-08-13
PCT/EP2011/063999 WO2012020143A1 (en) 2010-08-13 2011-08-12 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013538566A JP2013538566A (ja) 2013-10-17
JP2013538566A5 true JP2013538566A5 (enExample) 2014-09-18

Family

ID=44582954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523643A Pending JP2013538566A (ja) 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体

Country Status (4)

Country Link
US (2) US9012609B2 (enExample)
EP (1) EP2603522A1 (enExample)
JP (1) JP2013538566A (enExample)
WO (1) WO2012020143A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
WO2012020143A1 (en) * 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
PL2825556T3 (pl) 2012-03-16 2018-10-31 Albumedix A/S Warianty albuminy
AU2013343503B2 (en) 2012-11-08 2017-12-14 Albumedix Ltd. Albumin variants
US20160222087A1 (en) * 2013-09-13 2016-08-04 Novozymes Biopharma Dk A/S Albumin variants
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
SI3374392T1 (sl) * 2015-11-13 2022-04-29 Ablynx Nv Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin
KR20230074598A (ko) 2016-05-18 2023-05-30 모더나티엑스, 인크. 릴랙신을 인코딩하는 폴리뉴클레오타이드
KR20230061582A (ko) * 2016-12-07 2023-05-08 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
LT3571225T (lt) 2017-01-17 2024-11-11 Ablynx Nv Patobulintos serumo albumino rišamosios medžiagos
RS66173B1 (sr) 2017-01-17 2024-12-31 Ablynx NV Poboljšana veziva serumskog albumina
JP7200138B2 (ja) 2017-02-16 2023-01-06 ソネット バイオセラピューティクス,インコーポレイテッド アルブミン結合ドメイン融合タンパク質
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004035751A2 (en) 2002-10-18 2004-04-29 The Regents Of The University Of California Methods for crystallographic structure determination employing hydrogen exchange analysis
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
CA2569240A1 (en) 2004-06-01 2005-12-15 Domantis Limited Drug fusion comprising a polypeptide drug and an immunoglobulin heavy chain variable domain specific for serum albumin
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2006059106A2 (en) 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
EP1976991A1 (en) 2006-01-24 2008-10-08 Domantis Limited Fusion proteins that contain natural junctions
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688433A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
KR101740066B1 (ko) 2008-12-05 2017-05-25 글락소 그룹 리미티드 프로테아제 저항성 폴리펩티드를 선택하는 방법
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
KR101819754B1 (ko) * 2009-02-19 2018-01-18 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
ES2654929T3 (es) 2009-02-19 2018-02-15 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
CN102574914A (zh) 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
CA2774552A1 (en) * 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
WO2012020143A1 (en) * 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants

Similar Documents

Publication Publication Date Title
JP2013538566A5 (enExample)
RU2577228C2 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013529080A5 (enExample)
JP2016539096A5 (enExample)
JP2017520575A5 (enExample)
HRP20161043T1 (hr) Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2
RS66117B1 (sr) Poboljšana veziva serumskog albumina
RS66173B1 (sr) Poboljšana veziva serumskog albumina
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2019123112A (ru) Анти-il-5 антитела
IL266907B1 (en) Improved serum albumin binding immunoglobulin single variable domains
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2013519721A5 (enExample)
JP2017506075A5 (enExample)
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2009539349A5 (enExample)
JP2012515556A5 (enExample)
JP2015530983A5 (enExample)
JP2021530207A (ja) 二重特異性抗体及びその使用
JP2018509887A5 (enExample)
JP2014534237A5 (enExample)
JP2014530001A5 (enExample)
US20150175708A1 (en) Multifunctional Antibodies Binding to EGFR and MET
JP2016512214A5 (enExample)